Navigation Links
Horizons AMI trial data to be presented at TCT 2007
Date:10/15/2007

WASHINGTON, DC OCTOBER 15, 2007 -- The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. The study is designed to examine the safety and effectiveness of stents and anticoagulants in heart attack patients undergoing angioplasty.

The HORIZONS AMI trial data will be presented at a press conference on Wednesday, October 24 at 8:40 am. The results will be presented as a late breaking trial on Wednesday, October 24 at 10:50 am.

This is a landmark trial, which will help set guidelines for drug and stent therapy during primary angioplasty in patients with heart attacks for many years to come, said Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center.

While previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the highest risk form of heart attack (ST-elevation myocardial infarction).

Usually, angioplasty is associated with an excess of bleeding in heart attack patients, Dr. Stone said. However, using the anticoagulant bivalirudin with angioplasty in patients with stable coronary artery disease instead of heparin and glycoprotein IIb/IIIa inhibitors reduces bleeding, which has been associated with greater long-term survival. In the HORIZONS AMI trial, we have sought to determine whether using bivalirudin in patients with a heart attack, who undergo angioplasty, provides the same benefit.

This study should determine if bivalirudin use is as efficacious as the standard anticoagulant therapy, without causing excess bleeding in these acutely ill patients with a heart attack undergoing angioplasty, Dr. Mehran, Medical Director of the Data Coordinating and Analysis Center at CRF stated. She and her team conducted this study under an Investigational Device Exemption (IDE) from the Food and Drug Administration.

The HORIZONS AMI trial enrolled over 3600 patients presenting to hospitals in 11 countries with a heart attack. More than 120 national and international interventional cardiology centers are participating in the trial. Patients undergoing angioplasty were randomly assigned to receive either the standard anticoagulant unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor or bivalirudin alone. The patients are to be followed for five years.

Thirty-day outcome data will be presented, the primary endpoint of the study.

Comparison of Drug-Eluting Stents to Bare-Metal Stents Underway Patients enrolled in the HORIZONS AMI trial were also randomly assigned to receive either Taxus drug-eluting stents or a bare-metal stent. Data on this portion of the study also a landmark comparison of drug-eluting stents to bare-metal stents will be available next year.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology: